SLE is an autoimmune condition causing symptoms such as joint swelling AstraZeneca has received approval from the US Food and ...

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

Presentation Date / Time : Friday, May 1, 2026 / 2:55 p.m. to 6:00 p.m. EDT ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

Obexelimab Phase 3 win, SLE catalyst, pipeline updates (ZB014, orelabrutinib), and cash runway—read now. Click for a ZBIO ...

That’s what the autoimmune disease lupus does, 1 and when it strikes, it can cause significant symptoms, including extreme ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...

AstraZeneca plc (NASDAQ:AZN) has been granted approval by the U.S. Food and Drug Administration for a new self-injection ...

Objectives To assess indirect costs (IDC) due to lost productivity in paid/unpaid labour, stratified by sex, in a national ...

Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...